China Feihe, an infant-formula manufacturer, warns of declining profits ahead of its first-half financial results release in August. The company follows a trend of financial caution in the infant-nutrition sector.
Feihe, China’s largest infant-formula company with 17% market share, reports declining 2023 revenues driven by China’s falling birth rate and intensified industry competition. The company attributes its profit slump to weaker demand for baby formula amid demographic shifts. High competitive pressure further strains its financial performance in the sector.
Feihe, China’s leading infant formula manufacturer, reports a **33.5% decline in group profit for FY23**, citing persistent challenges tied to the country’s declining birth rate. The company’s financial performance reflects broader market pressures in the infant nutrition sector amid China’s demographic shift. Feihe’s results highlight ongoing struggles for formula producers as consumer demand weakens due to fewer newborns.
China Feihe’s annual revenue dropped 8.3% year-over-year to **19.5 billion yuan**, while its profit declined **33.5%** to **3.3 billion yuan**. Despite these financial setbacks, investors continue to show strong interest in the infant formula manufacturer. The company’s struggles in profitability and revenue growth contrast with its market appeal among backers.
